This inventor holds 1 USPTO granted patent and 3 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignee: Maxion Therapeutics Limited. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: John Mccafferty: Innovator in Sodium Channel Inhibitors
Introduction
John Mccafferty is a notable inventor based in Sawston, GB. He has made significant contributions to the field of medicine through his innovative work on sodium channel inhibitors. His research focuses on the development of binding members for sodium channel Nav1.7, which have potential applications in treating pain and epilepsy.
Latest Patents
Mccafferty holds a patent for sodium channel inhibitors that includes binding members comprising a fusion protein containing a Nav1.7-binding peptide. This peptide can be derived from venom toxin or knottin, which is inserted within an antibody variable domain. The binding members are designed to enhance specificity for Nav1.7 over other sodium channels, making them a promising avenue for medical treatments.
Career Highlights
John Mccafferty is associated with Maxion Therapeutics Limited, where he continues to advance his research in sodium channel inhibitors. His work is pivotal in the ongoing quest to develop effective treatments for conditions such as chronic pain and epilepsy.
Collaborations
Mccafferty collaborates with talented individuals in his field, including Aneesh Karatt Vellatt and Sachin Badrinath Surade. These partnerships enhance the innovative potential of his research and contribute to the advancement of medical science.
Conclusion
John Mccafferty's contributions to the field of sodium channel inhibitors exemplify the impact of innovative research on medicine. His work holds promise for improving treatment options for patients suffering from pain and epilepsy.